STML


Street Watch: Top Analysts Make Moves on 3 Buy-Rated Stocks

Onward and upward the market goes, with December providing further cheer as new record highs for the S&P 500 were notched in the …

Stemline Therapeutics (STML): Elzonris Approval Dawning on the Horizon, Says Analyst

Earlier this week, Stemline Therapeutics (STML) showcased clinical data of Elzonris (tagraxofusp) in blastic plasmacytoid dendritic cell neoplasm (BPDCN), chronic myelomonocytic leukemia (CMML) …

3 Biotech Stocks That Could Explode Higher in 2019

Black Friday is past. So is Cyber Monday.

Stemline Therapeutics (STML) Gets One Step Closer to EMA Approval; Analyst Weighs in With U.S. Angle

Stemline Therapeutics (STML) announced the European Medicines Agency (EMA) is granting accelerated assessment for the company’s marketing authorization for oral treatment, Elzonris. The …

Cowen Puts Stemline Therapeutics Inc’s (STML) Stock Collapse Into Perspective

Stemline Therapeutics Inc (NASDAQ:STML) was mentioned cautiously in an article by Adam Feuerstein of TheStreet. According to to the report, a patient died …

Roth Capital Reiterates Buy On Stemline Following 3Q14 Results

Roth Capital analyst Joseph Pantginis reiterated a Buy rating on Stemline Therapeutics Inc (NASDAQ:STML) with a price target of $62, which represents a …

Stemline Is Poised For A Significant Increase In Visibility, Says Roth Capital

In a research report issued Monday, Roth Capital analyst Joseph Pantginis reiterated a Buy rating on Stemline Therapeutics (NASDAQ:STML) with a price target …

Roth Capital Reiterates Buy On Stemline Therapeutics, $62 PT

In a research report issued today, Roth Capital analyst Joseph Pantginis reiterated a Buy rating on Stemline Therapeutics Inc (NASDAQ:STML) with a price …

Roth Capital Reiterates Buy On Stemline Following Initiation Of Clinical Development Program

In a research report published today, Roth Capital analyst Joseph Pantginis reiterated a Buy rating on Stemline Therapeutics, Inc. (STML) with a $62 price target, following today’s news of the opening of STML’s Investigational New …

2014 Should Represent The Year Of Going “Pivotal” For Stemline, Says Roth Capital

In a research note released today, Roth Capital analyst Joseph Pantginis reiterated a Buy rating on Stemline Therapeutics, Inc. (STML) and a price target of $62.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts